


ML192

Cat. No.:	HY-122246												
CAS No.:	460331-61-7												
Molecular Formula:	C ₂₀ H ₂₂ N ₄ O ₂ S												
Molecular Weight:	382.48												
Target:	GPR55; PKC; ERK; Arrestin												
Pathway:	GPCR/G Protein; Neuronal Signaling; Epigenetics; TGF-beta/Smad; MAPK/ERK Pathway; Stem Cell/Wnt												
Storage:	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>6 months</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 month</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	6 months		-20°C	1 month
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	6 months											
	-20°C	1 month											



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (261.45 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.6145 mL	13.0726 mL	26.1452 mL
		5 mM	0.5229 mL	2.6145 mL	5.2290 mL
		10 mM	0.2615 mL	1.3073 mL	2.6145 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (6.54 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.54 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (6.54 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	ML192 is a selective ligand antagonist of GPR55. ML192 inhibits the β-arrestin trafficking, ERK1/2 phosphorylation and PKCβ II translocation ^[1] .		
IC₅₀ & Target	ERK2	ERK1	PKCβII
In Vitro	ML192 inhibits the β-arrestin trafficking induced by 10 μM L-α lysophosphatidylinositol (LPI) or 1 μM ML186 with IC ₅₀ values		

of 0.70 μM and 0.29 μM , respectively^[1].

ML192 significantly inhibits ERK1/2 phosphorylation in GPR55-expressing U2OS cells with an IC_{50} value of 1.1 μM ^[1].

ML192 (0, 10, 30 and 100 μM) reduces the translocation of PKC β II in cells with the Wild-Type GPR55 receptor^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Kotsikorou E, et al. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. *Biochemistry*. 2013 Dec 31;52(52):9456-69.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA